Collectively, our findings suggest that synthetic peptides targeting CD36 hold strong therapeutic potential in mitigating aging-associated endothelial dysfunction and improving lung inflammatory syndromes in aging populations. This evidence concerns the gene CD36 and endothelial dysfunction.